Based on the above analysis, we selected three molecular markers (CCDC170, COL14A1, THBS2) that are expected to be used in clinical ovarian cancer and verified them by Western blotting and immunofluorescence experiments. The gene discussed is CCDC170; the disease is ovarian carcinoma.